Eledon Pharmaceuticals, Inc.
ELDNHealthcareNASDAQBiotechnology · Last scanned Jul 17, 2026
Scan Results
Daily timeframeEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company carries a $296.4M market cap, placing it firmly in the micro-cap category. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Market Cap
$296.4M
Beta
0.96
P/E (TTM)
—
P/E (Fwd)
-5.31
EPS (TTM)
$-0.73
EPS (Fwd)
$-0.72
ROE
-72.7%
ROA
-35.1%
Cash
$111.1M
Total Debt
$555,000
Free CF
-$39.7M
52W Change
2.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $111.1M in cash comfortably exceeding the $555K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$39.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -72.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ELDN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.